|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
| Process |
STA Standard
|
| ID number |
6207
|
Project Team
| Project lead |
Emily Richards |
Email enquiries
|
Date
|
Update
|
|
29 February 2024 - 28 March 2024
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6207 |
|
29 February 2024
|
In progress. Scoping commenced. |
|
23 January 2024
|
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late August 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late October 2024. |
|
09 August 2023
|
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-May 2024 when we will write to stakeholders about how they can get involved. The deadline for submissions is expected in approximately late-July 2024. |
|
01 February 2023
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
|
20 December 2022
|
As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207].
Please note that following on from advice received from the company the timelines for this appraisal are to be confirmed. The appraisal will be rescheduled to align with latest regulatory expectations and an update on the revised timelines will be provided when further information is available. |
For further information on our processes and methods, please see our CHTE processes and methods manual